Supported by a deep bench of industry expertise and our ground breaking technology, Innoquest is proud to serve clinicians, hospitals, medical centres, and their patients through the deployment of advanced diagnostic testing methods and technology.
At Innoquest, our values of intelligence, innovation and precision means a commitment to the latest and most updated technology and delivering unparalleled customer service
Innoquest remains the only community-based medical laboratory led and managed by clinicians and seasoned lab operators. We continuously work with service providers to make available the latest tests and technologies and ensure the highest standards are met in every diagnostic field.
Throughout childhood, adulthood and old age, pathology continues to help prevent, diagnose and treat infections, allergies, chronic diseases, cancer and countless other medical conditions.
Innoquest is born of two well established and respected private laboratories in Singapore – Quest Laboratories (Quest) and Innovative Diagnostics (Innovative Diagnostics) – with its name representing the two individual brands. Innoquest will lead the way by building a laboratory of the future to support doctors, patients and the wider medical community.
Pathology Asia Holdings (PAH), acquired Quest and Innovative Diagnostics in September 2018. After a year of planning and restructuring, we started our journey to merge the 2 entities into one, forming Innoquest Diagnostics Pte Ltd.
In 2022, we are proud to announce the establishment of Innoquest in Indonesia.
Our commitment to quality is assured, with our laboratory standards ensuring that ISO (15189) and international accreditation (CAP) will be achieved. We are aiming to lead the way by building a laboratory of the future that will support doctors, and the medical community of Indonesia by delivering the best laboratory services to help bring up successful diagnosis and treatment for the patients.
Innoquest has sister laboratory facilities in Singapore, Malaysia, Vietnam, Philippines and Australia.